Inhibikase Therapeutics pivots to focus on IkT-001Pro for pulmonary arterial hypertension after risvodetinib's failure in Parkinson's disease, leveraging imatinib's prior data. The company is well ...

Inhibikase Therapeutics (NASDAQ:IKT) has been able to receive a study may proceed letter from the FDA for the use of its drug IKT-001Pro for the treatment of patients with pulmonary arterial ...

A downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was ...

Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company ...

BOSTON and ATLANTA, Aug. 26, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Inhibikase Therapeutics ( (IKT)) has provided an announcement. Inhibikase Therapeutics entered an At the ...

Following the completion of the '501' trial, Inhibikase will initiate a discussion with the FDA on the parameters for approval of IkT-001Pro under the 505(b)(2) statute. About IkT-001Pro IkT ...

Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing. Get stock ...

BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...